Extracted from this filing and checked against the source text.
Debt Financings
SEC 8-K Item 2.03/2.04
confidence 0.9
Serina Therapeutics, Inc. incurred convertible notes of $500,000 with Juvenescence Limited maturing February 14, 2024.
- Instrument
- convertible notes
- Principal
- $500,000
- Counterparty
- Juvenescence Limited
- Maturity
- February 14, 2024
- Event
- incurrence
Exact text from the filing
On May 19, 2023, AgeX drew $500,000 of its credit available under the Allonge and Second Amendment to Amended and Restated Convertible Promissory Note (“Secured Note”) dated May 9, 2023 with Juvenescence Limited (“Juvenescence”). The Repayment Date on which the outstanding principal balance of the Secured Note will become due and payable shall be February 14, 2024.
View on SEC.gov
Listing & Compliance Notices
SEC 8-K Item 3.01
confidence 0.9
Serina Therapeutics, Inc. received a nyse_american delisting notice notice regarding stockholders equity (rules 1003(a)(i), 1003(a)(ii), 1003(a)(iii)).
- Exchange
- nyse american
- Notice
- delisting notice
- Deficiency
- stockholders equity
- Rules
- 1003(a)(i), 1003(a)(ii), 1003(a)(iii)
Exact text from the filing
May 17, 2023, AgeX received a notice from the staff of the NYSE American (the “Exchange”) indicating that they intend to commence proceedings to delist AgeX common stock from the Exchange based upon AgeX’s non-compliance with the stockholders’ equity requirements set forth in Sections 1003(a)(i), (ii) and (iii) of the Exchange’s Company Guide by the end of a compliance plan period that expired on May 17, 2023. Specifically, AgeX does not meet the continued listing standards because it has stockholders equity of less than (A) $2,000,000 and has incurred losses from continuing operations and/or
View on SEC.gov